摘要
目的:研究分析美罗培南治疗新生儿重症多重耐药菌感染的临床效果及安全性。方法:将90例重症多重耐药菌感染新生患儿,随机分为参照组和试验组各45例,参照组给予患儿替加环素常治疗,试验组在此基础上给予美罗培南治疗。对两组临床疗效及安全性进行观察比较。结果:90例患儿细菌学检验均为阳性,当中革兰阴性菌为62.22%(56株),革兰阳性菌24.44%(22株),真菌13.33%(12株)。试验组总有效率为82.22%,明显高于参照组的53.33%,并且试验组不良反应生情况显著低于参照组,差异均有统计学意义(P<0.05)。结论:对新生儿重症多重耐药菌感染采用美罗培南可有效提高临床疗效,并减少不良反应生情况,具较高的安全性。
Objective：To study the clinical efficacy and safety of meropenem in the treatment of neonatal intensive multidrug-resistant infections.Method：A total of 90 newborns with severe multidrug resistant bacteria infection were randomly divided into two groups：the control group（n=45） and the experimental group（n=45）.The control group was given tigacycline therapy,and the experimental group was treated with meropenem.The clinical efficacy and safety of the two groups were compared.Result：The bacteriological test of 90 children was positive,while the gram-negative bacteria were 62.22%（56 strains）,gram-positive bacteria 24.44%（22 strains）,and fungi 13.33%（12 strains）.The overall efficacy of the experimental group was 82.22%,which was significantly higher than the 53.33% of the reference group,and the adverse reaction of the experimental group was significantly lower than that of the reference group,and the difference was statistically significant（P〈0.05）.Conclusion：It can effectively improve the clinical efficacy and reduce adverse reactions in neonates with severe multidrug-resistant bacterial infection.
作者
林娟娟
牛迪
/LIN Juanjuan;NIU Di(The First People＇s Hospital of Xiangyang,Xiangyang 441000,China)
出处
《中外医学研究》
2018年第33期18-19,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
美罗培南
新生儿
重症多重耐药菌感染
疗效
Meropenem
The newborn
Severe multidrug-resistant bacterial infection
The curative effect
